EGFR and colorectal carcinoma: Concordantly, only KRAS wild-type (wt) patients seem to derive full benefit from anti-EGFR therapy, and as a consequence, clinical use of cetuximab and panitumumab in CRC is currently restricted to patients bearing KRAS wt tumors [11–16].